HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO MicroPort MedBot - The Core Products, the Business Model and the Concerns

Pre-IPO Hangzhou Bioer Technology - Concerns Behind the Outstanding Performance

Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns

Sihuan Pharmaceutical (460 HK) - The Logic Behind the Rally of the Stock Price

LG Uplus: A 100 Billion Won in Buyback, Bi-Annual Dividends, & A Potential Partnership with Disney

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

Tinavi Medical Technologies / Equity Bottom-Up

<p><a href="https://www.smartkarma.com/entities/tinavi-medical-technologies-co-ltd" target="_blank" data-smartkarma-citation="entities:33453:1" rel="noopener">Tinavi Medical Technologies (688277 CH)</a>, currently the only and first public domestic surgical robot company, was listed on the SSE STAR Market in July 2020. After the IPO, the stock price was as high as RMB141.6/share, but now it has fallen to RMB41/share on June 8, 2021, down over 245%. In fact, the operating performance shed some light. From 2017 to 2020, Tinavi sold 16, 20, 41 and 30 robots respectively, with total sales of 107 robots in four years, and achieved revenue of RMB73 million, RMB127 million, RMB230 million and RMB136 million, and corresponding net profit/loss of RMB21 million, RMB-366,000, RMB-34 million and RMB-54 million, respectively from 2017 to 2020. This article mainly analyzed the potential reasons for poor performance, the concerns on business model and the comparison with peers.</p>

Tinavi Medical Technologies (688277 CH), currently the only and first public domestic surgical robot company, was listed on the SSE STAR Market in July 2020. After the IPO, the stock price was as high as RMB141.6/share, but now it has fallen to RMB41/share on June 8, 2021, down over 245%. In fact, the operating performance shed some light. From 2017 to 2020, Tinavi sold 16, 20, 41 and 30 robots respectively, with total sales of 107 robots in four years, and achieved revenue of RMB73 million, RMB127 million, RMB230 million and RMB136 million, and corresponding net profit/loss of RMB21 million, RMB-366,000, RMB-34 million and RMB-54 million, respectively from 2017 to 2020. This article mainly analyzed the potential reasons for poor performance, the concerns on business model and the comparison with peers.

Shandong Weigao Group Medical Polymer Co (1066 HK)

Tinavi Medical Technologies (688277.CH) - Time Is Running Out for Tinavi